Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) declared a 3.1% quarterly dividend increase, raising the payout from $1.30 to $1.34 per share and marking the 64th consecutive year of annual increases. The new indicated annual dividend is $5.36 versus $5.20 previously.
The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026; the ex-dividend date is May 26, 2026.
Johnson & Johnson (NYSE: JNJ) reported Q1 2026 reported sales of $24.1 billion, up 9.9%, with adjusted Q1 EPS of $2.70 and GAAP diluted EPS of $2.14. The company raised 2026 guidance to estimated reported sales of $100.8 billion (midpoint, +7.0%) and adjusted EPS midpoint of $11.55 (+7.1%).
The quarter included multiple regulatory approvals and launches (ICOTYDE, TECNIS PureSee, TECVAYLI plus DARZALEX FASPRO, VARIPULSE Pro) and an estimated Q1 free cash flow of about $1.5 billion. An Enterprise Business Review is planned for December 8, 2026.
Johnson & Johnson (NYSE: JNJ) presented clinical data April 10, 2026 for the FDA-approved TECNIS PureSee IOL at ASCRS showing strong distance and intermediate vision, high spectacle independence for distance/intermediate, and low bothersome visual symptoms across U.S., Europe and Asia Pacific studies.
Key metrics: a 293-patient real-world study and a 200-patient randomized U.S. trial reported mean binocular uncorrected distance vision ~20/19, spectacle independence up to 96% for distance, and patient satisfaction rates of 93–97%.
Johnson & Johnson (NYSE: JNJ) launched VARIPULSE Pro in Europe after CE Mark approval on April 7, 2026, advancing its pulsed field ablation portfolio.
VARIPULSE Pro features a new pulse sequence with a lower temperature profile, claims 5x faster ablation versus the prior sequence while achieving equivalent lesions, and integrates with the CARTO 3 System. Twelve-month interim VARIPURE study data will be presented at EHRA 2026. VARIPULSE Pro is not approved in the United States.
Johnson & Johnson (NYSE: JNJ) reported 52-week Phase 3 results for ICOTYDE (icotrokinra) in moderate-to-severe plaque psoriasis showing sustained skin clearance and a favorable safety profile.
ADVANCE 1 PASI100 rose from 41% to 49%, ADVANCE 2 from 33% to 48%; adolescents reached 57% PASI100 and 61% IGA 0 at Week 52. No new safety signals were identified.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of ICOTYDE (icotrokinra) on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and adolescents 12+ who weigh ≥40 kg.
ICOTYDE is the first oral IL‑23 receptor peptide; Phase 3 data (2,500 patients) showed ~70% IGA 0/1 and 55% PASI 90 at Week 16 with adverse reaction rates within 1.1% of placebo through Week 16 and no new safety signals through Week 52.
Johnson & Johnson (NYSE:JNJ) presented Phase 1 Erda-iDRS data at EAU 2026 showing an 89% complete response rate in intermediate-risk non–muscle-invasive bladder cancer with a median complete-response duration of 18 months (95% CI, 14–25). Median recurrence-free survival in high-risk patients was 20 months.
Treatment met its primary safety endpoint, showed predominantly local adverse events, limited systemic exposure, and supports ongoing Phase 2 and Phase 3 MoonRISe studies.
Johnson & Johnson (NYSE: JNJ) announced U.S. FDA approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens for cataract surgery, cleared March 12, 2026. The lens preserves contrast sensitivity comparable to an aspheric monofocal IOL and reported 97% patient absence of very bothersome visual disturbances. TECNIS PureSee IOL will be available in the U.S. later in 2026 and expands JNJ’s TECNIS surgical vision portfolio, which has served nearly 500,000 eyes globally.
Johnson & Johnson (NYSE:JNJ) announced U.S. FDA approval of TECVAYLI plus DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy. The approval is based on Phase 3 MajesTEC-3 results showing large, statistically significant benefits in PFS and OS versus standard regimens.
Key results: PFS hazard ratio 0.17 (83% risk reduction), three-year PFS 83% vs 30%; OS hazard ratio 0.46, three-year OS 83.3% vs 65.0%. Safety signals include high infection rates and cytokine release syndrome that was mainly Grade 1/2.
Johnson & Johnson (NYSE: JNJ) announced that nipocalimab received U.S. FDA Fast Track designation for adults with systemic lupus erythematosus (SLE) on March 3, 2026. The designation recognizes unmet need and may expedite development and review timelines.
Nipocalimab showed reduced lupus disease activity and potential steroid-sparing in a Phase 2 study (JASMINE), and Johnson & Johnson is enrolling adults in the Phase 3 GARDENIA study.